ADAPTILENS ANNOUNCES $17.5M SERIES A FINANCING

Adaptilens selected as a finalist for the 2020 MassChallenge Boston program

Adaptilens was honored to be selected as part of the 2020 MassChallenge Boston cohort, joining 100 innovative early-stage startups chosen from over 1,100 applicants worldwide. As a healthcare and life sciences venture, Adaptilens benefited from the program’s virtual format, gaining access to mentorship, a global network of experts, and corporate partnerships to advance its mission of developing accommodating intraocular lenses that restore the eye’s natural focusing ability.

Updates

November 15, 2024
Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.
Read More
November 12, 2024
We’re excited to share that Adaptilens has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for this nomination. We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. Read the full announcement here: https://lnkd.in/e548JKAk #NEVYsSurvivor #NEVCA #Innovation
October 19, 2024
Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.